HK1207827A1 - Cylodextrin complexation methods for formulating peptide proteasome inhibitors - Google Patents

Cylodextrin complexation methods for formulating peptide proteasome inhibitors

Info

Publication number
HK1207827A1
HK1207827A1 HK15108517.0A HK15108517A HK1207827A1 HK 1207827 A1 HK1207827 A1 HK 1207827A1 HK 15108517 A HK15108517 A HK 15108517A HK 1207827 A1 HK1207827 A1 HK 1207827A1
Authority
HK
Hong Kong
Prior art keywords
cylodextrin
proteasome inhibitors
peptide proteasome
complexation methods
formulating peptide
Prior art date
Application number
HK15108517.0A
Other languages
English (en)
Chinese (zh)
Inventor
Evan Lewis
Peter Shwonek
Sean Dalziel
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1207827(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of HK1207827A1 publication Critical patent/HK1207827A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
HK15108517.0A 2012-05-08 2015-09-01 Cylodextrin complexation methods for formulating peptide proteasome inhibitors HK1207827A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
US201361777475P 2013-03-12 2013-03-12
PCT/US2013/040127 WO2013169897A1 (en) 2012-05-08 2013-05-08 Cylodextrin complexation methods for formulating peptide proteasome inhibitors

Publications (1)

Publication Number Publication Date
HK1207827A1 true HK1207827A1 (en) 2016-02-12

Family

ID=48326170

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108517.0A HK1207827A1 (en) 2012-05-08 2015-09-01 Cylodextrin complexation methods for formulating peptide proteasome inhibitors
HK18110388.9A HK1250927A1 (zh) 2012-05-08 2018-08-14 用於配製肽蛋白酶體抑制劑的環糊精絡合法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18110388.9A HK1250927A1 (zh) 2012-05-08 2018-08-14 用於配製肽蛋白酶體抑制劑的環糊精絡合法

Country Status (15)

Country Link
US (1) US10159746B2 (xx)
EP (1) EP2662094B1 (xx)
JP (1) JP6410264B2 (xx)
KR (4) KR20190137963A (xx)
CN (2) CN107693772A (xx)
AU (2) AU2013259573B2 (xx)
CA (1) CA2873044C (xx)
CL (1) CL2014003055A1 (xx)
EA (1) EA033614B1 (xx)
FI (1) FI2662094T3 (xx)
HK (2) HK1207827A1 (xx)
IL (1) IL235553B (xx)
MX (2) MX364393B (xx)
SG (2) SG10201609318UA (xx)
WO (1) WO2013169897A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014290012B2 (en) 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
MX2018016387A (es) 2016-06-29 2019-09-09 Kezar Life Sciences Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.
AR108919A1 (es) 2016-06-29 2018-10-10 Kezar Life Sciences Proceso de preparación del inhibidor de inmunoproteasoma de péptido epoxicetona, y sus precursores
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
AU2017369971B2 (en) * 2016-11-29 2023-06-01 Oculis Operations Sàrl Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
KR20190141244A (ko) * 2017-05-03 2019-12-23 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 및 부설판을 함유하는 조성물
CN110882221B (zh) * 2019-11-29 2021-06-29 健进制药有限公司 一种注射用卡非佐米冻干制剂的生产工艺
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
EP0889056B1 (en) 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
PT1326632E (pt) 2000-10-12 2007-01-31 Viromics Gmbh Tratamento para o tratamento de infecções por vírus da hepatite
BRPI0418386A (pt) * 2003-12-31 2007-05-22 Cydex Inc formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide
PT1745064E (pt) * 2004-04-15 2011-03-23 Proteolix Inc Compostos para a inibição de uma enzima de proteassoma
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
HUE027850T2 (en) 2004-12-07 2016-11-28 Onyx Therapeutics Inc Preparation for proteasome inhibition
EP1954320A2 (en) * 2005-11-15 2008-08-13 Baxter International Inc. Compositions comprising lipoxygenase inhibitors and cyclodextrin
DK2207791T4 (da) * 2007-10-04 2019-10-07 Onyx Therapeutics Inc Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
ES2617560T3 (es) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
US9493582B2 (en) 2012-02-28 2016-11-15 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same

Also Published As

Publication number Publication date
SG10201609318UA (en) 2016-12-29
MX364393B (es) 2019-04-24
EA033614B1 (ru) 2019-11-11
KR20200130748A (ko) 2020-11-19
CL2014003055A1 (es) 2015-02-13
CN107693772A (zh) 2018-02-16
MX2019004845A (es) 2021-03-31
AU2018200444A1 (en) 2018-02-08
EP2662094B1 (en) 2024-04-17
SG11201407337QA (en) 2014-12-30
HK1250927A1 (zh) 2019-01-18
CA2873044A1 (en) 2013-11-14
FI2662094T3 (fi) 2024-06-26
US10159746B2 (en) 2018-12-25
AU2018200444B2 (en) 2019-10-31
IL235553A0 (en) 2015-01-29
AU2013259573B2 (en) 2018-02-15
AU2013259573A1 (en) 2014-11-27
JP6410264B2 (ja) 2018-10-24
KR20150008165A (ko) 2015-01-21
CN104411334A (zh) 2015-03-11
EA201491994A1 (ru) 2015-04-30
KR102054329B1 (ko) 2019-12-10
JP2015516430A (ja) 2015-06-11
KR20190137963A (ko) 2019-12-11
KR20220088949A (ko) 2022-06-28
MX2014013552A (es) 2015-05-08
WO2013169897A1 (en) 2013-11-14
US20150111838A1 (en) 2015-04-23
EP2662094A1 (en) 2013-11-13
IL235553B (en) 2018-04-30
CA2873044C (en) 2021-01-26

Similar Documents

Publication Publication Date Title
ZA201207384B (en) Cylodextrin complexation methods for furmulating peptide proteasome inhibitors
HK1250927A1 (zh) 用於配製肽蛋白酶體抑制劑的環糊精絡合法
EP2755192A4 (en) VISUALALLY DISTANCE DRIVING DETECTION DEVICE
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
EP2687055A4 (en) ENHANCED DETECTION OF THE POSITION OF A DEVICE
EP2877457A4 (en) CYSTATHIONINE -LYASE INHIBITORS (CSE)
EP2877458A4 (en) CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER
EP2685271A4 (en) MAGNETIC DETECTION DEVICE
EP2785183A4 (en) TRIAZOLOPYRIDINONE PDE10 INHIBITORS
EP2725338A4 (en) TIRE TEST DEVICE
EP2787496A4 (en) OBJECT DETECTION DEVICE
GB2502243B (en) Ion detection
EP2869903A4 (en) FILLING PROCESS FOR PEPTIDE SOLUTIONS
EP2797320A4 (en) DEVICE FOR DETECTING OBJECTS
EP2665453A4 (en) DEVICE FOR REACHING A HEMOSTASE
GB2494284B (en) Detection aid device
EP2772636A4 (en) DEVICE FOR DETECTING CATALYST DEGRADATION
GB2492805B (en) Apparatus for measuring an article
SG10201500486QA (en) Probing device
EP2755184A4 (en) OBJECT DETECTION DEVICE
ZA201300859B (en) Sweep design for seismic sources
GB2490789B (en) A device for withdrawing objects from a narrow space
EP2661633A4 (en) PROOF OF PROTEOLYSIS
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
GB2495391B (en) Detection device